Home Cart Sign in  
Chemical Structure| 2222094-18-8 Chemical Structure| 2222094-18-8

Structure of BC1618
CAS No.: 2222094-18-8

Chemical Structure| 2222094-18-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BC1618 is an orally active Fbxo48 inhibitor that promotes mitochondrial fission and autophagy while enhancing liver insulin sensitivity, offering potential applications in metabolic disease research.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BC1618

CAS No. :2222094-18-8
Formula : C24H24F3NO2
M.W : 415.45
SMILES Code : OC(COC1=CC=C(C(F)(F)F)C=C1)CN(CC2=CC=CC=C2)CC3=CC=CC=C3
MDL No. :MFCD33548907
InChI Key :LGTYABNNHILKHF-UHFFFAOYSA-N
Pubchem ID :134417552

Safety of BC1618

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

Description
BC1618, an orally active compound that inhibits Fbxo48, induces Ampk-dependent signaling by preventing the degradation of activated pAmpkα mediated by Fbxo48. BC1618 enhances mitochondrial fission, promotes autophagy, and enhances hepatic insulin sensitivity [1].

In Vitro:

Cell Line
Concentration Treated Time Description References
BEAS-2B cells 10 μM 5 h Promoted mitochondrial fission observed via Mito Tracker staining and confocal microscopy Nat Chem Biol. 2021 Mar;17(3):298-306
MDA-MB-468 cells 10 μM 48 h To evaluate the effect of BC1618 on tumor cell growth. Results showed that BC1618 did not affect the growth or proliferation of tumor cells. Adv Sci (Weinh). 2025 Apr;12(14):e2409835
CAR-T cells 10 μM 48 h To evaluate the enhancement of BC1618 on the antitumor activity of CAR-T cells. Results showed that BC1618 significantly strengthened the antitumor response of CAR-T cells. Adv Sci (Weinh). 2025 Apr;12(14):e2409835
Huh-7 human hepatic cells 30 µM 24 h To evaluate the effect of BC1618 on GDF15 mRNA levels, results showed that BC1618 significantly increased GDF15 mRNA levels more than metformin. Molecules. 2023 Jul 17;28(14):5468

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice High fat diet-induced obese mice Oral gavage 20 mg/kg Two doses, 2 hours apart Improved hepatic insulin sensitivity and reduced insulin-stimulated hepatic glucose production Nat Chem Biol. 2021 Mar;17(3):298-306
NCG mice Triple-negative breast cancer model Intratumoral injection 10 μM Single injection, observed for 20 days To evaluate the antitumor effect of BC1618 combined with hydrogel-delivered CAR-T cells in vivo. Results showed that BC1618 significantly enhanced the antitumor activity of CAR-T cells. Adv Sci (Weinh). 2025 Apr;12(14):e2409835

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.41mL

0.48mL

0.24mL

12.04mL

2.41mL

1.20mL

24.07mL

4.81mL

2.41mL

References

 

Historical Records

Categories